Iterum Therapeutics Plc Stock Today

ITRM Stock  USD 1.40  0.03  2.19%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Very High

 
High
 
Low
Iterum Therapeutics is selling at 1.40 as of the 1st of March 2025; that is 2.19 percent increase since the beginning of the trading day. The stock's lowest day price was 1.32. Iterum Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 1st of December 2024 and ending today, the 1st of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
25th of May 2018
Category
Healthcare
Classification
Health Care
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 34.58 M outstanding shares of which 1.85 M shares are currently shorted by private and institutional investors with about 2.87 trading days to cover. More on Iterum Therapeutics PLC

Moving together with Iterum Stock

  0.79EXAS EXACT SciencesPairCorr
  0.83FATE Fate TherapeuticsPairCorr

Moving against Iterum Stock

  0.6OPT OptheaPairCorr
  0.54GANX Gain TherapeuticsPairCorr
  0.47PFE Pfizer IncPairCorr
  0.46LTRN Lantern PharmaPairCorr
  0.43CUE Cue BiopharmaPairCorr
  0.41TMO Thermo Fisher ScientificPairCorr

Iterum Stock Highlights

CEO, DirectorCorey Fishman
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00160.0017
Notably Down
Slightly volatile
Total Current Liabilities15.5 M17.6 M
Fairly Down
Slightly volatile
Non Current Liabilities Total31.4 M31.1 M
Fairly Up
Slightly volatile
Total Assets56.1 M44.6 M
Significantly Up
Slightly volatile
Total Current Assets32.6 M24.8 M
Significantly Up
Pretty Stable
Debt Levels
Iterum Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Iterum Therapeutics' financial leverage. It provides some insight into what part of Iterum Therapeutics' total assets is financed by creditors.
Liquidity
Iterum Therapeutics PLC currently holds 45.53 M in liabilities with Debt to Equity (D/E) ratio of 0.58, which is about average as compared to similar companies. Iterum Therapeutics PLC has a current ratio of 9.28, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Iterum Therapeutics' use of debt, we should always consider it together with its cash and equity.

Change In Working Capital

(12.09 Million)
Iterum Therapeutics PLC (ITRM) is traded on NASDAQ Exchange in USA. It is located in 3 Dublin Landings, Dublin, Ireland, D01 C4E0 and employs 9 people. Iterum Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 48.24 M. Iterum Therapeutics PLC conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 34.58 M outstanding shares of which 1.85 M shares are currently shorted by private and institutional investors with about 2.87 trading days to cover. Iterum Therapeutics PLC currently holds about 68.91 M in cash with (26.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Iterum Therapeutics Probability Of Bankruptcy
Ownership Allocation
Iterum Therapeutics PLC has a total of 34.58 Million outstanding shares. Roughly 90.29 (percent) of Iterum Therapeutics outstanding shares are held by general public with 1.18 % owned by insiders and only 8.53 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Iterum Ownership Details

Iterum Stock Institutional Holders

InstituionRecorded OnShares
Tower Research Capital Llc2024-12-31
710
Barclays Plc2024-12-31
500
Activest Wealth Management2024-12-31
133
Wells Fargo & Co2024-12-31
85.0
Cypress Capital Management, Llc2024-12-31
66.0
Planning Capital Management Corp2024-09-30
40.0
Newbridge Financial Services Group, Inc.2024-12-31
15.0
Sbi Securities Co Ltd2024-12-31
14.0
Nelson, Van Denburg & Campbell Wealth Management Group, Llc2024-12-31
13.0
Renaissance Technologies Corp2024-12-31
438.8 K
New Leaf Venture Partners, L.l.c.2024-12-31
345 K
View Iterum Therapeutics Diagnostics

Iterum Therapeutics Historical Income Statement

At this time, Iterum Therapeutics' Interest Income is very stable compared to the past year. As of the 1st of March 2025, Depreciation And Amortization is likely to grow to about 2.1 M, while Net Interest Income is likely to drop (2.6 M). View More Fundamentals

Iterum Stock Against Markets

Iterum Therapeutics Corporate Management

Sailaja MDChief OfficerProfile
Tom LoughmanSenior OperationsProfile
Steven MDSenior DevelopmentProfile
Louise BarrettSenior SecretaryProfile
Michael MDStrategic DirectorProfile
Judith MatthewsChief OfficerProfile
When determining whether Iterum Therapeutics PLC is a strong investment it is important to analyze Iterum Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iterum Therapeutics' future performance. For an informed investment choice regarding Iterum Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.26)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.33)
Return On Equity
(5.56)
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.